網誌文章搜尋建議

給多發性硬化症MS病友和親友的建議:
如要搜尋站內相關文章可多利用
"搜尋此網誌的文章內容"的功能,這樣就可以快速的找到你想要得資訊而不需要從第一篇開始看了.
有關CCSVI(靜脈血管窄化及手術的資訊)可在相關連結以及相關MS blog內

推薦頻道:Gimmy a break

2010年1月27日 星期三

默克MS的口服藥Cladribine 在英國兩年的人體試驗結果

Two year Study of U.K. Cladribine for Multiple Sclerosis(from April 20, 2005 to January 18, 2007)
默克MS的口服藥Cladribine 在英國兩年的人體試驗結果

In Lima and Findlay Ohio, no one in the small multiple sclerosis (MS) communities have heard of the new oral Cladribine study, but this will soon change as news gets around and excitement rises.

Cladribine is a cytoxic agent that is usually administered through shots or IV infusions used to treat hairy cell leukemia, but a two year study in the U.K., led by Professor Gavin Giovannoni at Barts and The London School of Medicine and Dentistry, showed successful use of a tablet form taken orally in the treatment of MS.

The new study involved 1,320 patients from April 20, 2005 to January 18, 2007 from 155 clinical centers and 32 countries. The patients were given either two or four short treatment courses of Cladribine tablets per year or the placebo and monitored using MRI scans.

在1320位MS病患中,一年給予2~4次的Cladribine的服用

Patients allowed in the study had previously received a diagnosis of relapsing-remitting MS, had lesions consistent with MS and had at least one relapse within 12 months before entry and were able to have rescue therapy after week 24 with interferon beta-1a if a patient had more than one relapse or a sustained increase in their expanded disability status scale (EDSS) score.

The results show those who had taken the Cladribine tablets were over 55 percent less likely to suffer relapse and about 30 percent less likely to suffer a worsening in their disability. Cladribine works by suppressing the immune system which attacks the central nervous system of those afflicted with MS and is the first of it's kind in that it is taken orally instead of with shots.

研究顯示,超過55%的病人不會再發作,約30%的病人減緩了在肢體障礙的進程.

Adverse effects leading to the discontinuation of the study were low but still at least twice as frequent with high-dose Cladribine. Twenty cases of cutaneous herpes zoster (shingles) were recorded among patients receiving it, three of which were serious and three solid tissue cancers (pancreatic, ovarian, and melanoma) occurred among patients receiving low-doses (3.5 mg per kilogram).

其中有20個病例產生泡疹,紅疹, 這當中的3個當使用低劑量時情況較嚴重,有3個部位組織產生癌細胞.

Lymphocytopenia (a low white blood cell count) was also frequent in patients receiving Cladribine showing up more so, again, with higher doses.

"The introduction of an oral therapy, particularly one that has no short term side effects and is as easy to use as oral Cladribine, will have a major impact on the treatment of MS," says Professor Giovanni. "However, the use of this drug as a first line therapy will have to be weighed up against the potential long term risks which have yet to be defined."

Sources: New England Journal of Medicine; Queen Mary University of London; Barts and the London School of Medicine and Dentistry; Science Daily
Share/Bookmark

5 則留言:

  1. 西方藥廠通過賣藥,真是賺足了錢。在美國一個MS病人每年治療的花費平均是3萬美元。意大利醫生的革命性手術如果全面展開,最大的受益者將是MS病人,最大的輸家將是那些藥廠。

    回覆刪除
  2. 关于MS新药的消息,美国媒体广泛报道,但是对于意大利医生的新突破,美国的媒体基本保持沉默。为什么?因为新药物的报道,药厂会送钱给媒体来宣传,但是意大利医生的发现显然与药厂利益有冲突。

    当然,这种沉默终究会被打破。过几天,加拿大有一个关于CCSVI的国际会议召开,所有研究CCSVI的专家将发表他们近期的研究结果,包括意大利,美国,加拿大,波兰的所有专家。他们的研究结果将震动全世界!

    回覆刪除
  3. 我其實也覺得藥品的確是一個獨門生意,外科手術的發現也會對此造成衝擊,像極了白色巨塔中內外科醫生彼此之間的競爭.能夠彼此相互觀摩,才是進步之道啊!

    回覆刪除
  4. 關于新的靜脈狹窄理論,人們一直疑問的是究竟是MS導致靜脈狹窄,還是靜脈狹窄導致MS,也就是先有雞還是先有蛋的問題。最近,一個47國家專家參加的國際會議認定,MS病人的靜脈狹窄是先天的,也就是說是靜脈狹窄導致了MS。如果這個理論是正確的,那么最重要的治療應該是手術,因為藥物無法治療靜脈狹窄,當然藥物可以輔助治療MS。
    (有時候blogger 無法paste, 英文原文只有以后附上。)

    回覆刪除

留言